Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Public ClinicalTrials.gov record NCT01151423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura
Study identification
- NCT ID
- NCT01151423
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Interventions
- Caplacizumab Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2010
- Primary completion
- Feb 28, 2014
- Completion
- Feb 28, 2014
- Last update posted
- Apr 3, 2023
2011 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site | Los Angeles | California | 90033 | — |
| Investigator Site | Washington D.C. | District of Columbia | — | — |
| Investigator Site | Atlanta | Georgia | 30322 | — |
| Investigator Site | St Louis | Missouri | 63110 | — |
| Investigator Site | New York | New York | 10021 | — |
| Investigator Site | Rochester | New York | 14642 | — |
| Investigator Site | Valhalla | New York | 10595 | — |
| Investigator Site | Durham | North Carolina | 27710 | — |
| Investigator Site | Winston-Salem | North Carolina | 27157 | — |
| Investigator Site | Columbus | Ohio | 43210 | — |
| Investigator Site | Pittsburgh | Pennsylvania | 15224 | — |
| Investigator Site | Dallas | Texas | — | — |
| Investigator Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01151423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01151423 live on ClinicalTrials.gov.